Cargando…

Prognostic value of DAXX/ATRX loss of expression and ALT activation in PanNETs: is it time for clinical implementation?

Detalles Bibliográficos
Autor principal:	Marinoni, Ilaria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8995811/ https://www.ncbi.nlm.nih.gov/pubmed/33975869 http://dx.doi.org/10.1136/gutjnl-2021-324664

Ejemplares similares

ATRX/DAXX: Guarding the Genome against the Hazards of ALT
por: Clatterbuck Soper, Sarah F., et al.
Publicado: (2023)

Switch telomerase to ALT mechanism by inducing telomeric DNA damages and dysfunction of ATRX and DAXX
por: Hu, Yang, et al.
Publicado: (2016)

Systemic Treatment Selection for Patients with Advanced Pancreatic Neuroendocrine Tumours (PanNETs)
por: Megdanova-Chipeva, Vera G., et al.
Publicado: (2020)

Structural basis for DAXX interaction with ATRX
por: Wang, Xiaoman, et al.
Publicado: (2017)

A new immunohistochemistry prognostic score (IPS) for recurrence and survival in resected pancreatic neuroendocrine tumors (PanNET)
por: Viúdez, Antonio, et al.
Publicado: (2016)

Structural and biochemical characterization of DAXX-ATRX interaction
por: Li, Zhuang, et al.
Publicado: (2017)

Correction: A new immunohistochemistry prognostic score (IPS) for recurrence and survival in resected pancreatic neuroendocrine tumors (PanNET)
por: Viúdez, Antonio, et al.
Publicado: (2017)

Colorectal cancer patient-derived organoids and cell lines harboring ATRX and/or DAXX mutations lack Alternative Lengthening of Telomeres (ALT)
por: Falcinelli, Marta, et al.
Publicado: (2023)

Alternative lengthening of telomeres is not synonymous with mutations in ATRX/DAXX
por: de Nonneville, Alexandre, et al.
Publicado: (2021)

A systems biology approach to define mechanisms, phenotypes, and drivers in PanNETs with a personalized perspective
por: Werle, Silke D., et al.
Publicado: (2023)

Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size
por: Hackeng, Wenzel M, et al.
Publicado: (2022)

DAXX/ATRX and MEN1 genes are strong prognostic markers in pancreatic neuroendocrine tumors
por: Park, Joo Kyung, et al.
Publicado: (2017)

Prognostic Significance of Altered ATRX/DAXX Gene in Pancreatic Neuroendocrine Tumors: A Meta-Analysis
por: Wang, Fei, et al.
Publicado: (2021)

Formal reply to “Alternative lengthening of telomeres is not synonymous with mutations in ATRX/DAXX”
por: Feuerbach, Lars
Publicado: (2021)

Rapid and reversible suppression of ALT by DAXX in osteosarcoma cells
por: Yost, Kathryn E., et al.
Publicado: (2019)

Structural and mechanistic insights into ATRX-dependent and -independent functions of the histone chaperone DAXX
por: Hoelper, Dominik, et al.
Publicado: (2017)

Targeting Telomerase and ATRX/DAXX Inducing Tumor Senescence and Apoptosis in the Malignant Glioma
por: Fan, Hueng-Chuen, et al.
Publicado: (2019)

DAXX-ATRX regulation of p53 chromatin binding and DNA damage response
por: Gulve, Nitish, et al.
Publicado: (2022)

Context matters – Daxx and Atrx are not robust tumor suppressors in the murine endocrine pancreas
por: Sun, Chang, et al.
Publicado: (2022)

The Role of ATRX in the Alternative Lengthening of Telomeres (ALT) Phenotype
por: Amorim, João P., et al.
Publicado: (2016)

ATRX affects the repair of telomeric DSBs by promoting cohesion and a DAXX-dependent activity
por: Lovejoy, Courtney A., et al.
Publicado: (2020)

New players in heterochromatin silencing: histone variant H3.3 and the ATRX/DAXX chaperone
por: Voon, Hsiao P.J., et al.
Publicado: (2016)

Capitalizing on ATRX loss in glioma via PARP inhibition: Comment on “Loss of ATRX confers DNA repair defects and PARP inhibitor sensitivity” by Garbarino et al.
por: Zalenski, Abigail A, et al.
Publicado: (2021)

EBV Tegument Protein BNRF1 Disrupts DAXX-ATRX to Activate Viral Early Gene Transcription
por: Tsai, Kevin, et al.
Publicado: (2011)

Control of human adenovirus type 5 gene expression by cellular Daxx/ATRX chromatin-associated complexes
por: Schreiner, Sabrina, et al.
Publicado: (2013)

Loss of ATRX and DAXX expression identifies poor prognosis for smooth muscle tumours of uncertain malignant potential and early stage uterine leiomyosarcoma
por: Slatter, Tania L., et al.
Publicado: (2015)

ATRX, DAXX or MEN1 mutant pancreatic neuroendocrine tumors are a distinct alpha-cell signature subgroup
por: Chan, Chang S., et al.
Publicado: (2018)

PML protein organizes heterochromatin domains where it regulates histone H3.3 deposition by ATRX/DAXX
por: Delbarre, Erwan, et al.
Publicado: (2017)

Immunohistochemical analyses of the expression profiles of INSM1, ATRX, DAXX and DLL3 in solid papillary carcinomas of the breast
por: Yanai, Hirotsugu, et al.
Publicado: (2022)

Mutations inhibiting KDM4B drive ALT activation in ATRX-mutated glioblastomas
por: Udugama, M., et al.
Publicado: (2021)

KRAS and DAXX/ATRX Gene Mutations Are Correlated with the Clinicopathological Features, Advanced Diseases, and Poor Prognosis in Chinese Patients with Pancreatic Neuroendocrine Tumors
por: Yuan, Fei, et al.
Publicado: (2014)

Comparison of Oncological and Surgical Outcomes Between Formal Pancreatic Resections and Parenchyma-Sparing Resections for Small PanNETs (<2 cm): Pancreas2000 Research and Educational Program (Course 9) Study Protocol
por: Pea, Antonio, et al.
Publicado: (2020)

TOP3A amplification and ATRX inactivation are mutually exclusive events in pediatric osteosarcomas using ALT
por: de Nonneville, Alexandre, et al.
Publicado: (2022)

Development of a quality of life questionnaire for patients with pancreatic neuroendocrine tumours (the PANNET module)
por: Ramage, John K., et al.
Publicado: (2022)

ATRX loss induces multiple hallmarks of the alternative lengthening of telomeres (ALT) phenotype in human glioma cell lines in a cell line-specific manner
por: Brosnan-Cashman, Jacqueline A., et al.
Publicado: (2018)

Long non-coding RNA ChRO1 facilitates ATRX/DAXX-dependent H3.3 deposition for transcription-associated heterochromatin reorganization
por: Park, Jinyoung, et al.
Publicado: (2018)

Therapeutic Vulnerability to ATR Inhibition in Concurrent NF1 and ATRX-Deficient/ALT-Positive High-Grade Solid Tumors
por: Yuan, Ming, et al.
Publicado: (2022)

Loss of ATRX Does Not Confer Susceptibility to Osteoarthritis
por: Solomon, Lauren A., et al.
Publicado: (2013)

ATRX Loss in the Development and Prognosis of Conjunctival Melanoma
por: van Ipenburg, Jolique A., et al.
Publicado: (2023)

Mechanistic understanding of the role of ATRX in senescence provides new insight for combinatorial therapies with CDK4 inhibitors.
por: Kovatcheva, Marta, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_v3nia1cphl246jahcjdbdp3kbo